|1.||Bancone, Germana: 4 articles (01/2015 - 01/2013)|
|2.||White, Nicholas J: 4 articles (01/2014 - 01/2011)|
|3.||Castanys, Santiago: 4 articles (09/2011 - 12/2010)|
|4.||Gamarro, Francisco: 4 articles (09/2011 - 12/2010)|
|5.||Green, Justin: 3 articles (01/2015 - 01/2013)|
|6.||Carvalho, Luis: 3 articles (09/2011 - 12/2010)|
|7.||Sundar, Shyam: 3 articles (06/2011 - 12/2002)|
|8.||Walker, Larry A: 3 articles (02/2011 - 12/2006)|
|9.||Horton, John: 3 articles (12/2005 - 03/2003)|
|10.||Gut, Jiri: 2 articles (05/2015 - 02/2014)|
|1.||Visceral Leishmaniasis (Kala Azar)
12/01/2001 - "WR6026 demonstrated the unusual clinical features of lack of increased efficacy against Brazilian kala-azar with increased dosing above 2 mg/kg/day and toxicity that was not present in previous investigations."
06/01/2011 - "This randomized, open-label study of patients in India with visceral leishmaniasis (VL) investigated the effect of food on sitamaquine and desethyl-sitamaquine pharmacokinetics. "
12/01/2005 - "A phase II dose-ranging study of sitamaquine for the treatment of visceral leishmaniasis in India."
11/01/2005 - "A phase II dose-increasing study of sitamaquine for the treatment of visceral leishmaniasis in Kenya."
06/01/2011 - "Sitamaquine can be taken regardless of food intake, was generally well tolerated, and showed potential efficacy in patients with visceral leishmaniasis."
08/01/2006 - "In-vitro and in-vivo studies on a topical formulation of sitamaquine dihydrochloride for cutaneous leishmaniasis."
08/01/2006 - "The efficacy of topical formulations of the 8-aminoquinoline, sitamaquine dihydrochloride, in both in-vitro and in in-vivo models of cutaneous leishmaniasis is reported. "
08/01/2006 - "A range of topical sitamaquine dihydrochloride formulations (anhydrous gel, emulsions) were developed for studies on experimental cutaneous leishmaniasis using only topically acceptable excipients or those currently undergoing regulatory approval. "
05/01/2011 - "Sitamaquine is a 8-aminoquinoline in development for the treatment of visceral leishmaniasis by oral route, no activity being observed on the experimental cutaneous leishmaniasis experimental models. "
12/01/2002 - "The results of clinical trials of two oral compounds are reported - fluconazole in treating cutaneous leishmaniasis was found to be safe and effective, whereas sitamaquine (WR6026) for visceral leishmaniasis was found to be toxic with poor efficacy. "
12/01/2006 - "This review focuses on recent developments on evaluation of 8-aminoquinoline analogs with broader efficacy and reduced toxicity, which would provide better drugs for treatment of protozoal infections. "
11/01/1977 - "Radical cure of infections with Plasmodium cynomolgi: a function of total 8-aminoquinoline dose."
05/01/2015 - "The s-triazine hybrid containing two 8-aminoquinoline moieties and one chlorine atom emerged as the most potent against P. berghei liver-stage infection, active in the low nanomolar region, combined with good metabolic stability in rat liver microsomes. "
02/01/1983 - "The 8-quinolinamine, 4-[6-[6-methoxy-4-methyl-8-quinolinyl)amino]hexyl]-1-piperazineethanol (1b), has been shown to be highly effective against Leishmania donovani infections in hamsters. "
08/01/2004 - "Short report: the activity of pamaquine, an 8-aminoquinoline drug, against sporozoite-induced infections of Plasmodium vivax (New Guinea strains)."
|4.||Glucosephosphate Dehydrogenase Deficiency
01/01/2013 - "Review of key knowledge gaps in glucose-6-phosphate dehydrogenase deficiency detection with regard to the safe clinical deployment of 8-aminoquinoline treatment regimens: a workshop report."
01/01/2014 - "vivax liver stages can be eliminated only by radical treatment with a ≥ seven-day course of an 8-aminoquinoline, with the attendant risk of acute haemolytic anaemia in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency. "
01/01/2012 - "Hypnozoites are only eliminated by using an 8-aminoquinoline (currently only primaquine), which requires compliance with a long regimen as well as care to avoid those at risk of haemolysis due to the common genetic polymorphism, glucose-6-phosphate dehydrogenase deficiency. "
01/01/2014 - "The objective of this systematic review was to assess the risk of adverse effects in people with G6PD deficiency given primaquine or other 8-aminoquinoline (8AQ) as a single dose or short course (less than 7 days). "
01/01/2015 - "Accurate diagnosis of glucose-6-phosphate dehydrogenase (G6PD) deficiency is required to avoid the risk of acute hemolysis associated with 8-aminoquinoline treatment. "
|4.||Glucosephosphate Dehydrogenase (Glucose 6 Phosphate Dehydrogenase)
|5.||Succinic Acid (Succinate)
|9.||Excipients (Suspending Agents)
|1.||Drug Therapy (Chemotherapy)